152 related articles for article (PubMed ID: 36234745)
1. Drug-Inclusive Inorganic-Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate.
Vassaki M; Lazarou S; Turhanen P; Choquesillo-Lazarte D; Demadis KD
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234745
[TBL] [Abstract][Full Text] [Related]
2. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
3. Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model.
Khajuria DK; Razdan R; Mahapatra DR
Eur J Pharm Sci; 2015 Jan; 66():173-83. PubMed ID: 25444840
[TBL] [Abstract][Full Text] [Related]
4. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
Oryan A; Sahvieh S
Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation.
Khajuria DK; Vasireddi R; Trebbin M; Karasik D; Razdan R
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():698-708. PubMed ID: 27987763
[TBL] [Abstract][Full Text] [Related]
6. Controlled delivery of zoledronate improved bone formation locally in vivo.
Gou W; Wang X; Peng J; Lu Q; Wang Y; Wang A; Guo Q; Gao X; Xu W; Lu S
PLoS One; 2014; 9(3):e91317. PubMed ID: 24618585
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
8. In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.
Li X; Naguib YW; Cui Z
Int J Pharm; 2017 Jun; 526(1-2):69-76. PubMed ID: 28455136
[TBL] [Abstract][Full Text] [Related]
9. Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study.
Forte L; Torricelli P; Boanini E; Gazzano M; Fini M; Bigi A
Acta Biomater; 2017 May; 54():419-428. PubMed ID: 28238916
[TBL] [Abstract][Full Text] [Related]
10. Effect of local zoledronate on implant osseointegration in a rat model.
Back DA; Pauly S; Rommel L; Haas NP; Schmidmaier G; Wildemann B; Greiner SH
BMC Musculoskelet Disord; 2012 Mar; 13():42. PubMed ID: 22439827
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of strontium and zoledronate on hydroxyapatite structure and bone cell responses.
Boanini E; Torricelli P; Gazzano M; Della Bella E; Fini M; Bigi A
Biomaterials; 2014 Jul; 35(21):5619-26. PubMed ID: 24731709
[TBL] [Abstract][Full Text] [Related]
12. A bifunctional zoledronate sustained-release system in scaffold: Tumor therapy and bone repair.
Di W; Shuai Y; Bo W; Wei T; Jinpeng H; Qian G; Deng Y
Colloids Surf B Biointerfaces; 2023 Feb; 222():113064. PubMed ID: 36481508
[TBL] [Abstract][Full Text] [Related]
13. Self-sacrificial MOFs for ultra-long controlled release of bisphosphonate anti-osteoporotic drugs.
Vassaki M; Papathanasiou KE; Hadjicharalambous C; Chandrinou D; Turhanen P; Choquesillo-Lazarte D; Demadis KD
Chem Commun (Camb); 2020 May; 56(38):5166-5169. PubMed ID: 32255461
[TBL] [Abstract][Full Text] [Related]
14. Differences between bisphosphonates in binding affinities for hydroxyapatite.
Lawson MA; Xia Z; Barnett BL; Triffitt JT; Phipps RJ; Dunford JE; Locklin RM; Ebetino FH; Russell RG
J Biomed Mater Res B Appl Biomater; 2010 Jan; 92(1):149-55. PubMed ID: 19904734
[TBL] [Abstract][Full Text] [Related]
15. The role of zoledronic acid in the management of osteoporosis.
Maricic M
Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
[TBL] [Abstract][Full Text] [Related]
16. Cancellous bone healing around strontium-doped hydroxyapatite in osteoporotic rats previously treated with zoledronic acid.
Li Y; Shui X; Zhang L; Hu J
J Biomed Mater Res B Appl Biomater; 2016 Apr; 104(3):476-81. PubMed ID: 25891947
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
18. Effect of combined treatment with zoledronic acid and propranolol on mechanical strength in an rat model of disuse osteoporosis.
Khajuria DK; Razdan R; Mahapatra DR
Rev Bras Reumatol; 2015; 55(6):501-11. PubMed ID: 25480532
[TBL] [Abstract][Full Text] [Related]
19. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.
Nakamura Y; Shimizu T; Asano T; Shimodan S; Ishizu H; Takahashi D; Takahata M; Iwasaki N
J Bone Miner Metab; 2021 Sep; 39(5):824-832. PubMed ID: 33821302
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice.
Bonnet N; Lesclous P; Saffar JL; Ferrari S
PLoS One; 2013; 8(3):e58726. PubMed ID: 23505553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
